Professor Faiez Zannad

MD, PhD, Cardiologist, Clinical pharmacologist. Trained at Université de Lorraine, Université of Lyon, France and Medical Research Council (Oxford, UK). Currently, Emeritus Professor of Therapeutics at Université de Lorraine, France. As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi, MRAs and SGLT2i. As a clinical scientist his work focuses on fibrosis and biomarkers. He has served as a chairman of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum with meetings in Paris, Washington DC, in Asia and the Middle East. As a "highly cited researcher" he published more than 1,279 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as a Eugene Braunwald Scholar in 2019 at Harvard Medical School.